| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Pancreatic cancer is characterized by abundant quantity of the connective tissue framework and the interaction between cancer cells and connective tissue could be very important for the growth and invasiveness of cancer cells, leading partly to the poor outcome of the patients with pancreatic cancer. We evaluated the effects of heparin or NF-κB inhibitor, DHMEQ, on pancreatic cancer. Heparin showed not only anti-proliferation effects but also inhibition of liver metastasis on in vivo model. Gemcitabine showed angiogenesis inhibition, apoptosis induction and invasiveness inhibition rather than cell growth inhibition. The anti-tumor effects of combination therapy were promising.
|
